The 2012 ESC focused update establishes NOACs as the preferred stroke prevention strategy in non-valvular atrial fibrillation and standardizes the use of CHA2DS2-VASc and HAS-BLED scores.
Favors NOACs over VKAs for non-valvular AF stroke prevention; extends prior evidence into 2012 ESC guideline standards.
of the 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: Prepared by the Czech Society of Cardiology Robert Cihak, Luděk Haman, Petr Heinc Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic Department of Cardiovascular Medicine, University Hospital and Faculty of Medicine, Charles University Prague, Hradec Kralove, Czech Republic Department of Internal Medicine I, Cardiology, University Hospital Olomouc, Czech Republic
No takes yet. Share an insight, caveat, or question.
Čihák et al. (2012) conducted a review in Atrial fibrillation. New oral anticoagulants (NOACs) and updated risk stratification vs. Vitamin K antagonists (VKAs) and previous guidelines was evaluated. The 2012 ESC focused update recommends the CHA2DS2-VASc score for stroke risk assessment and prefers new oral anticoagulants over vitamin K antagonists for non-valvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: